Weekly administration of alendronate: rationale and plan for clinical assessment (Q33845884)

29 July 2017

1 reference

title

Weekly administration of alendronate: rationale and plan for clinical assessment (English)

1 reference

29 July 2017

Bone HG

1

1 reference

29 July 2017

Adami S

2

1 reference

29 July 2017

Rizzoli R

3

1 reference

29 July 2017

Favus M

4

1 reference

29 July 2017

Ross PD

5

1 reference

29 July 2017

Santora A

6

1 reference

29 July 2017

Prahalada S

7

1 reference

29 July 2017

Daifotis A

8

1 reference

29 July 2017

Orloff J

9

1 reference

29 July 2017

Yates J

10

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

Clinical Therapeutics

1 reference

29 July 2017

22

1 reference

29 July 2017

15-28

1 reference

29 July 2017

1

1 reference

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Esophagitis and alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Pharmacokinetics of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Preclinical pharmacology of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat. Comparison between effects on tibiae and vertebrae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Adverse effects of bisphosphonates. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Intramuscular clodronate therapy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Comparative study of potential for bisphosphonates to damage gastric mucosa of rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Esophageal irritation due to alendronate sodium tablets: possible mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Lineage commitment and maturation of epithelial cells in the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987974-6

7 January 2021

10.1016/S0149-2918(00)87974-6

Identifiers

DOI

1 reference

29 July 2017

1 reference